Pfizer Camptosar Sales Aid Cited By FDA For Minimizing Diarrhea Risk
FDA is citing a visual aid used by Pfizer sales reps for minimizing the risks of diarrhea associated with the cancer product Camptosar (irinotecan)
You may also be interested in...
Although FDA is issuing fewer warning letters, those issued are more likely to signal a potential enforcement action, FDA Associate Commissioner Peter Pitts suggested during the DTC National Conference & Expo in Boston March 30
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011